Decoy Therapeutics Inc. — Form S-1
Filed October 7, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 72/100
What the filing says
On September 23, 2026, Decoy Therapeutics closed a private placement with Armistice Capital Master Fund Ltd. whereby Armistice exercised 1,184,434 Series B warrants for $3.85M cash (at reduced exercise price of $3.25/share, down from $5.91). As inducement, Decoy issued Armistice 2,368,868 new warrants (200% of exercised amount) exercisable at $3.25/share for 5 years. This S-1 registers those new warrant shares for resale. Armistice now owns 4.37M shares (64.68% of outstanding common stock, subject to 4.99% beneficial ownership cap), and could own 1.99M shares post-offering.
Why this rating
Material financing for a $1.9B-market-cap company near going-concern threshold; $3.85M proceeds = ~200% of current market cap. Significant dilution (warrant issuance = 99% of current shares outstanding) and concentration risk. Moderate positive: cash extends runway into 2027; neutral-to-negative: heavy dilution and Nasdaq listing risk remain.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
Price action (we called it neutral)
before filing · preread $1.60 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.